COL16A1

Across TCGA pan-cancer cohorts, COL16A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COL16A1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COL16A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COL16A1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where COL16A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.321	0.492	.004	41	view →
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	39	view →
LSCC	DFS	Quartile	II,III,IV	0.473	0.887	.008	19	view →
COAD	DFS	Median	III,IV	0.835	1.000	.033	12	view →
LUAD	OS	Quartile	II,III,IV	0.398	0.771	.015	7	view →
HNSC	DFS	Tertile	All	0.978	0.897	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COL16A1–PDAC (DFS)

Open the PDAC breakdown →